Literature DB >> 15831631

Warfarin: a case history in pharmacogenetics.

A M Hall, M R Wilkins.   

Abstract

Both hereditary and environmental factors contribute to inter-individual variability in drug response. The considerable interest in the role of genes has to be balanced with the contribution of external influences. Warfarin provides a useful case study of the need to integrate both genetic and non-genetic information when selecting the right dose for a patient. This article discusses the latest data on genotype and warfarin sensitivity and the efforts to incorporate this information into normograms. Exploring the genetics of warfarin response will lead not only to safer prescribing but elucidate the mechanism of action of warfarin and enable the development of new anticoagulant drugs.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15831631      PMCID: PMC1768901          DOI: 10.1136/hrt.2004.051771

Source DB:  PubMed          Journal:  Heart        ISSN: 1355-6037            Impact factor:   5.994


  20 in total

1.  Testing drug response in the presence of genetic information: sampling issues for clinical trials.

Authors:  L R Cardon; R M Idury; T J Harris; J S Witte; R C Elston
Journal:  Pharmacogenetics       Date:  2000-08

2.  Impaired (S)-warfarin metabolism catalysed by the R144C allelic variant of CYP2C9.

Authors:  A E Rettie; L C Wienkers; F J Gonzalez; W F Trager; K R Korzekwa
Journal:  Pharmacogenetics       Date:  1994-02

3.  Clinical risk factors and timing of recurrent venous thromboembolism during the initial 3 months of anticoagulant therapy.

Authors:  J D Douketis; G A Foster; M A Crowther; M H Prins; J S Ginsberg
Journal:  Arch Intern Med       Date:  2000 Dec 11-25

4.  Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy.

Authors:  Mitchell K Higashi; David L Veenstra; L Midori Kondo; Ann K Wittkowsky; Sengkeo L Srinouanprachanh; Fred M Farin; Allan E Rettie
Journal:  JAMA       Date:  2002-04-03       Impact factor: 56.272

5.  Influence of cytochrome P-450 CYP2C9 polymorphisms on warfarin sensitivity and risk of over-anticoagulation in patients on long-term treatment.

Authors:  J Taube; D Halsall; T Baglin
Journal:  Blood       Date:  2000-09-01       Impact factor: 22.113

6.  A gene-anchored map position of the rat warfarin-resistance locus, Rw, and its orthologs in mice and humans.

Authors:  M H Kohn; H J Pelz
Journal:  Blood       Date:  2000-09-01       Impact factor: 22.113

7.  Genetic modulation of oral anticoagulation with warfarin.

Authors:  M Margaglione; D Colaizzo; G D'Andrea; V Brancaccio; A Ciampa; E Grandone; G Di Minno
Journal:  Thromb Haemost       Date:  2000-11       Impact factor: 5.249

8.  Allelic variants of human cytochrome P450 2C9: baculovirus-mediated expression, purification, structural characterization, substrate stereoselectivity, and prochiral selectivity of the wild-type and I359L mutant forms.

Authors:  R L Haining; A P Hunter; M E Veronese; W F Trager; A E Rettie
Journal:  Arch Biochem Biophys       Date:  1996-09-15       Impact factor: 4.013

9.  A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarin.

Authors:  Giovanna D'Andrea; Rosa Lucia D'Ambrosio; Pasquale Di Perna; Massimiliano Chetta; Rosa Santacroce; Vincenzo Brancaccio; Elvira Grandone; Maurizio Margaglione
Journal:  Blood       Date:  2004-09-09       Impact factor: 22.113

10.  Influence of CYP2C9 and CYP2C19 genetic polymorphisms on warfarin maintenance dose and metabolic clearance.

Authors:  Maria Gabriella Scordo; Vittorio Pengo; Edoardo Spina; Marja Liisa Dahl; Milena Gusella; Roberto Padrini
Journal:  Clin Pharmacol Ther       Date:  2002-12       Impact factor: 6.875

View more
  2 in total

1.  Warfarin anticoagulation: a survey of patients' knowledge of their treatment.

Authors:  S M Moran; N Fitzgerald; M Pope; M Madden; C J Vaughan
Journal:  Ir J Med Sci       Date:  2011-06-25       Impact factor: 1.568

2.  Correlation between Rs2108622 Locus of CYP4F2 Gene Single Nucleotide Polymorphism and Warfarin Dosage in Iranian Cardiovascular Patients.

Authors:  Shahdah Khosropanah; Seyed Nooreddin Faraji; Hamzeh Habibi; Majid Yavarian; Roohollah Mansoori; Sezaneh Haghpanah
Journal:  Iran J Pharm Res       Date:  2017       Impact factor: 1.696

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.